None listed
Conditions
Brief summary
The purpose of this study is to collect clinical data on Colorectal cancer patients with Stage II and Stage III disease and process this on the colorectal cancer data registry in order to generate a personalised care plan summary. Who is it for? You may be eligible for this study if you are a patient with Stage II or III colon cancer and fit for chemotherapy. You may also be eligible for this study if you are a GP monitoring patients with colorectal cancer fitting the inclusion criteria. Study details A personalised care plan summary will be provided during the second consultation visit with the oncologist and has the following components including cancer stage, planned treatment, planned follow-up visits and cancer helpline resources. This care plan summary will be created by your oncologist and will take an additional 10 minutes to generate the care plan from the database and then go through the information with you. You will be requested to complete a questionnaire after completion of your treatment. It is hoped that results generated from this study will help us determine if the provision of a personalised care plan can be extended to other tumour streams to help other patients.
Interventions
Patients at Footscray Hospital will receive a personalised care plan summary which has the following components including Cancer stage, Planned treatment, Planned follow-up visits and Cancer helpline resources. The care plan summary will be generated and provided to the patient during their second consultation with the oncology clinician. The consultation with the clinician will usually take approximately 30 minutes where they are provided the care plan and informed that they will be asked to complete a survey about how useful the care plan is in 6 months. The patient will be approached to complete the survey at a further consultation with the clinician. The care plan summary will be generated from a HREC approved colorectal registry which all colorectal cancer patients at Footscray Hospital are entered into. This study utilised a waiver of consent approach where the participants will be told about the study and a questionnaire which will be provided to them for completion after they have completed their first course of the treatment. No written consent will be obtained from the participants. The duration of the study is approximately 7 months. The plan is to roll this out to other centres and for other tumour streams if determined to be an effective communication tool.
Sponsors
Eligibility
Inclusion criteria
• Patients with Stage II or III colon cancer • Patients referred to oncology following surgery • Patients fit for adjuvant chemotherapy and/or routine surveillance • GPs who are seeing participants on the study
Exclusion criteria
• Colorectal patients with Stage I or IV disease • Primary rectal cancer patients